Influenza News and Research

Latest Influenza News and Research

Interim data from Sanofi Pasteur's Influenza A 2009 Monovalent Vaccine clinical trials in infants and children

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today an interim analysis of data from clinical trials of the U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine in infants and children 6 months through 9 years of age. The data indicate the vaccine is immunogenic and that one dose may protect many children.

15 Oct 2009

Surveillance of travel-related illness helps to detect and respond to H1N1 influenza

Because pandemics unfold in unpredictable ways, surveillance of travel-related illness is among the most powerful tools health officials and doctors can use to detect and respond to new pathogens like the novel H1N1 influenza, says the physician who heads the University of Alabama at Birmingham (UAB) Travelers' Clinic.

15 Oct 2009

Atlantic examines flu vaccine, antiviral skepticism

As countries around the world roll out H1N1 (swine flu) virus vaccine campaigns, the Atlantic examines, "[W]hat if everything we think we know about fighting influenza is wrong?"

15 Oct 2009

Richmont Sciences to market PURE’s antimicrobial SDC disinfectants

PURE Bioscience announced that it has expanded its business strategy through an alliance with the Dallas-based sales and marketing team Richmont Sciences, LLC, which will begin actively selling PURE’s revolutionary new antibacterial, antiviral and antifungal hard surface disinfectant and its active ingredient.

14 Oct 2009

Patients who are severely ill with H1N1 are at risk for developing PE, says study

Researchers utilizing computed tomography (CT) scans have found that patients with severe cases of the H1N1 virus are at risk for developing severe complications, including pulmonary emboli (PE), according to a study to be published online Oct. 14, 2009, in the American Journal of Roentgenology. The study will be published in the December issue of the AJR.

14 Oct 2009

DIATHERIX Laboratories granted EUA for H1N1-09 Influenza Test

DIATHERIX Laboratories, Inc. is pleased to announce it has been granted emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its DIATHERIX H1N1-09 Influenza Test.

14 Oct 2009

Sinovac Biotech announces receipt of Panflu vaccine distribution approval in Hong Kong

Sinovac Biotech Ltd., a leading developer and provider of vaccines in China, announced today that its wholly-owned subsidiary, Sinovac Biotech (Hong Kong) Ltd, has received the Certificate of Approval to distribute Panflu(TM) (H5N1), its H5N1 (bird flu) pandemic influenza vaccine, in Hong Kong. The certificate is valid through September 13, 2014 and thereafter will be renewable for periods of five years at a time, subject to payment of the registration fee.

14 Oct 2009

Nobilon initiates a clinical Proof of Concept trial with SCH 900795 vaccine

Nobilon, the human vaccine business unit of Schering-Plough Corporation (NYSE: SGP), today announced that it has initiated a clinical Proof of Concept trial with SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal use.

14 Oct 2009

Inovio Biomedical's proprietary DNA vaccine development platform introduced

Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, president and CEO, presented at the invitation-only World Knowledge Forum being held in Seoul, South Korea.

14 Oct 2009

Imaging as a tool to identify severe cases of H1N1

Researchers at the National Institutes of Health (NIH) have found that imaging can now be used as a tool for identifying severe cases of H1N1 and may play a key role in understanding the pathogenesis of the virus, possibly leading to earlier diagnoses of severe cases in the future, according to a study published online today in the American Journal of Roentgenology. The study will be published in the December issue of AJR.

14 Oct 2009

H1N1 patients with ARDS survive illness when treated with ECMO

Despite the severity of disease and the intensity of treatment, most patients in Australia and New Zealand who experienced respiratory failure as a result of 2009 influenza A(H1N1) and were treated with a system that adds oxygen to the patient's blood survived the disease, according to a study to appear in the November 4 issue of JAMA.

14 Oct 2009

Statewide H1N1 Vaccine Provider Registration System from Upp Technology

Supporting directives from the U.S. Centers for Disease Control and Prevention, Upp Software, a business unit of Upp Technology, Inc., has developed, delivered and now offers a Statewide H1N1 Vaccine Provider Registration System to accommodate thousands of vaccine providers' ordering and reporting needs.

14 Oct 2009

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

NanoBio Corporation today announced an award from the National Institute of Allergy and Infectious Diseases, a Division of The National Institute of Health, to fund vaccine research associated with “Innate Immune Receptors and Adjuvant Discovery.” NanoBio is the principal subcontractor for the $9.3 million contract awarded to the University of Michigan.

14 Oct 2009

Do not underestimate the serious impact of the H1N1 virus, say researchers

A research team has warned medical experts in the Northern Hemisphere not to underestimate the serious impact of the H1N1 (Swine flu) virus with a new report showing that many patients who were critically ill with the virus required prolonged life support treatment with heart-lung machines.

14 Oct 2009

Rapid rollout of H1N1 vaccines is effective in reducing infection rates according to simulation model

Early action, especially rapid rollout of vaccines, is extremely effective in reducing the attack rate of the H1N1 influenza virus, according to a simulation model of a pandemic outbreak reported in a new study in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

14 Oct 2009

American Lung Association to raise awareness about the seriousness of seasonal influenza

In the spirit of "healthy competition," the American Lung Association in Minnesota is teaming up with the Minneapolis and St. Paul Fire Departments to raise awareness about the seriousness of seasonal influenza and the importance of vaccination this year.

14 Oct 2009

New Ultra Sensitive facemasks to protect against seasonal and swine flu

BIOSAFE, Inc., a company that manufactures and sells a novel antimicrobial polymer, has announced that they are launching in specific markets outside the United States through a unique facemask treated with BIOSAFE(®). Crosstex' new BIOSAFE-treated Ultra Sensitive facemasks begin to reduce microorganisms such as MRSA, VRE, and Staph immediately upon contact, and have further proven to be effective against Influenza A strains such as seasonal flu and the novel H1N1 virus.

14 Oct 2009

Studies examine H1N1 treatment, outcome differences in Mexico, Canada

New studies suggest that "[d]eveloping countries with limited access to advanced health-care facilities may be in for a rough ride with swine [H1N1] flu and even countries with high-tech ICUs may find themselves pushed to the limit as their hospitals struggle to save gravely ill H1N1 patients," the Canadian Press reports.

14 Oct 2009

NIH awards $2.2m grant to Smiths Detection to develop a test for multiple types of influenza

Smiths Detection today announces the award of a $2.2m, two-year grant from the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health (NIH), to develop a test for multiple types of influenza.

14 Oct 2009

Study says critical illness among Canadian patients with H1N1 occurred rapidly after hospital admission

Critical illness among Canadian patients with 2009 influenza A(H1N1) occurred rapidly after hospital admission, often in young adults, and was associated with severely low levels of oxygen in the blood, multi-system organ failure, a need for prolonged mechanical ventilation, and frequent use of rescue therapies, according to a study to appear in the November 4 issue of JAMA.

13 Oct 2009

Influenza News and Research

Latest Influenza News and Research

Interim data from Sanofi Pasteur's Influenza A 2009 Monovalent Vaccine clinical trials in infants and children

Surveillance of travel-related illness helps to detect and respond to H1N1 influenza

Atlantic examines flu vaccine, antiviral skepticism

Richmont Sciences to market PURE’s antimicrobial SDC disinfectants

Patients who are severely ill with H1N1 are at risk for developing PE, says study

DIATHERIX Laboratories granted EUA for H1N1-09 Influenza Test

Sinovac Biotech announces receipt of Panflu vaccine distribution approval in Hong Kong

Nobilon initiates a clinical Proof of Concept trial with SCH 900795 vaccine

Inovio Biomedical's proprietary DNA vaccine development platform introduced

Imaging as a tool to identify severe cases of H1N1

H1N1 patients with ARDS survive illness when treated with ECMO

Statewide H1N1 Vaccine Provider Registration System from Upp Technology

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

Do not underestimate the serious impact of the H1N1 virus, say researchers

Rapid rollout of H1N1 vaccines is effective in reducing infection rates according to simulation model

American Lung Association to raise awareness about the seriousness of seasonal influenza

New Ultra Sensitive facemasks to protect against seasonal and swine flu

Studies examine H1N1 treatment, outcome differences in Mexico, Canada

NIH awards $2.2m grant to Smiths Detection to develop a test for multiple types of influenza

Study says critical illness among Canadian patients with H1N1 occurred rapidly after hospital admission

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Influenza News and Research

Latest Influenza News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in